Compare Ginkgo Bioworks Holdings Inc (DNA) vs Quantum Computing Inc (QUBT) Price & Performance

Ginkgo Bioworks (DNA) trades at $7.42, down 3.01% with bearish technical signals. The company reported Q2 2026 revenue of $20M, down 48% year-over-year, while maintaining a high gross margin of 68.04% but significant net losses. Analyst sentiment is mixed with 45% buy ratings amid ongoing business model transition to autonomous laboratory systems and contract research services.

The outlook remains challenging with persistent revenue declines and negative cash flow, though recent earnings beats provide some optimism. Key risks include execution of the business pivot and path to profitability. Wall Street shows cautious optimism with majority buy ratings despite fundamental headwinds.

Quantum Computing Inc. (QUBT) trades at $8.91, down 0.22% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of $5.6 million, a significant increase year-over-year, though it posted a net loss. Analyst sentiment is positive with a 75% buy rating and a consensus price target of $18.50, suggesting substantial upside potential from current levels.

QUBT presents high-risk, high-reward potential as it transitions to commercial scaling, with strong revenue growth offset by persistent losses and negative margins. Key risks include execution challenges in manufacturing expansion and intense competition in the quantum computing sector. The stock's valuation remains steep with a P/S ratio of 189.05, requiring careful monitoring of profitability improvements.